You are here

Article info

Article menu

Download PDFPDF

XML
Hepatology
Original article
Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal

Authors

  • Naoki Ikenaga Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Zhen-Wei Peng Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA Department of Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China PubMed articlesGoogle scholar articles
  • Kahini A Vaid Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Susan B Liu Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Shuhei Yoshida Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Deanna Y Sverdlov Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Amanda Mikels-Vigdal Gilead Sciences, Foster City, California, USA PubMed articlesGoogle scholar articles
  • Victoria Smith Gilead Sciences, Foster City, California, USA PubMed articlesGoogle scholar articles
  • Detlef Schuppan Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA Institute of Translational Immunology and Research Center for Immune Therapy, University Medical Center, Mainz, Germany PubMed articlesGoogle scholar articles
  • Yury V Popov Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Yury V Popov, Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02115, USA; ypopov{at}bidmc.harvard.edu
View Full Text

Citation

Ikenaga N, Peng Z, Vaid KA, et al
Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal
Gut 2017;66:1697-1708.

Publication history

  • Received June 21, 2016
  • Revised December 7, 2016
  • Accepted December 18, 2016
  • First published January 10, 2017.
Online issue publication 
December 06, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/